NEUROPACE INC (NPCE) Stock Price, Forecast & Analysis
NASDAQ:NPCE • US6412881053
NPCE Key Statistics, Chart & Performance
The current stock price of NPCE is 15.05 USD. In the past month the price decreased by -13.26%. In the past year, price increased by 22.26%.
NPCE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NPCE. When comparing the yearly performance of all stocks, NPCE is one of the better performing stocks in the market, outperforming 78.68% of all stocks.
NPCE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NPCE. Both the profitability and financial health of NPCE have multiple concerns.
NPCE Financial Highlights
Over the last trailing twelve months NPCE reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.36% | ||
| ROE | -129.53% | ||
| Debt/Equity | 3.17 |
NPCE Forecast & Estimates
14 analysts have analysed NPCE and the average price target is 19.89 USD. This implies a price increase of 32.16% is expected in the next year compared to the current price of 15.05.
For the next year, analysts expect an EPS growth of 22.69% and a revenue growth 24.22% for NPCE
NPCE Ownership
NPCE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.62 | 193.832B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.53 | 169.664B | ||
| SYK | STRYKER CORP | 24.21 | 139.908B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.34 | 109.921B | ||
| BDX | BECTON DICKINSON AND CO | 11.16 | 50.66B | ||
| IDXX | IDEXX LABORATORIES INC | 42.48 | 49.283B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.52 | 44.358B | ||
| RMD | RESMED INC | 20.57 | 35.869B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16 | 35.845B | ||
| DXCM | DEXCOM INC | 27.73 | 25.383B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NPCE
Company Profile
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Company Info
NEUROPACE INC
455 N. Bernardo Avenue
Mountain View CALIFORNIA US
CEO: Michael Favet
Employees: 209
Phone: 16502372700
NEUROPACE INC / NPCE FAQ
Can you describe the business of NEUROPACE INC?
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
What is the stock price of NEUROPACE INC today?
The current stock price of NPCE is 15.05 USD. The price increased by 3.79% in the last trading session.
Does NEUROPACE INC pay dividends?
NPCE does not pay a dividend.
What is the ChartMill rating of NEUROPACE INC stock?
NPCE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for NPCE stock?
NEUROPACE INC (NPCE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.76).
Can you provide the upcoming earnings date for NEUROPACE INC?
NEUROPACE INC (NPCE) will report earnings on 2026-03-10, after the market close.
What is the outstanding short interest for NEUROPACE INC?
The outstanding short interest for NEUROPACE INC (NPCE) is 3.55% of its float.